Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

On Friday, Merck & Co Inc (NYSE:MRK) agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.

The drug company will pay an upfront $700 million in cash to privately held Curon Biopharmaceuticals for CN201, a clinical-stage bispecific antibody for B-cell diseases. Curon will also be ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon ...

The big pharma is paying $700 million upfront for full global rights to CN201, a CD3xCD19 bispecific which is in early-stage clinical development for B-cell-associated diseases, including cancers ...

The international biopharmaceutical company Merck Group (MSD outside the USA and Canada) has entered into a final agreement with the Chinese private biotechnology company Curon Biopharmaceutical to ...

Prime Minister Netanyahu warned Iran of severe consequences for its missile attacks on Israel, emphasizing Israel's determination to retaliate decisively. Information ...

Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon Biopharmaceutical, enhancing its pipeline with ...

Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline ...